Click Here to return To Results

 

Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome Stroke 49:e41-e42, Bala, M.M.,et al, 2018 See this aricle in Pubmed Article Abstract Based on the gathered data, the review was unable to conclude on the benefits or harms of any of the following interventions: (1) nonvitamin K antagonist oral anticoagulants versus standard VKA anticoagulation; (2) antiplatelet plus VKA agents versus single or dual antiplatelet therapy; and (3) dual versus single antiplatelet therapy, for the secondary prevention of recurrent thrombosis in patients with APS. Likewise, there was insufficient evidence to draw any conclusion on the benefits of using high-intensity versus standard-intensity VKA although there was some evidence of harm (increased risk of minor and any bleeding) associated with high-intensity VKA. Five ongoing randomized controlled trials will likely provide additional data on the therapy of APS.

Related Tags

(click to filter results - removes previous filter) anticoagulant,treatment anticoagulant,treatment,combined antiphospholipid antibody syndrome cerebrovascular accident cerebrovascular accident,prevention of cerebrovascular accident,secondary prevention controversies in neurology platelet inhibiting drugs review article

Click Here to return To Results